NCT07147621 Evaluation of Chemotherapy-induced Cognitive Disorders During the Treatment of Hematological Malignancies
| NCT ID | NCT07147621 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Angers |
| Condition | Acute Myeloid Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2026-02-26 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2026-02-26 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chemotherapy-induced cognitive disorders, such as memory problems, slowness of execution, inability to concentrate, and language difficulties, are sequelae that occur in patients undergoing chemotherapy or who have received chemotherapy. These symptoms lead to a degradation of the patients' quality of life and can have a significant social and familial impact. They are most commonly described in solid oncology, particularly in patients with breast cancer. Data about patients with hematological malignancies are scarce, but they seem to show the same phenomenon as in solid oncology. Indeed, many chemotherapies are used both in hematology and solid oncology and may therefore cause similar effects on cognition. Additionally, due to their mechanism of action, some chemotherapies specifically used in hematology could induce cognitive disorders. Hematology-treated patients are probably also affected by these disorders and may consequently experience a reduced quality of life. The objective of this study is to assess the changes in cognitive functions in patients receiving chemotherapy for the treatment of hematological malignancies, using neuropsychological tests and a self-administered questionnaire, compared to a control group, as well as their potential impact on quality of life, fatigue, anxiety, and depression.
Eligibility Criteria
Inclusion Criteria: * Patient group inclusion criteria: * adult patient with acute myeloid leukemia, Hodgkin's lymphoma, or non-Hodgkin's lymphoma; * patient receiving a fixed-duration first-line chemotherapy; * patient affiliated or beneficiary of a social security scheme; .signed inform consent form. * Control group inclusion criteria: * adult; * patient's relative (spouse, brother, sister, friend, etc.); * less than 5 years of difference with the patient; * same educational level (\< baccalaureate/high school degree, baccalaureate/high school degree level, 2-year university degree, \> 2-year university degree); * person affiliated or beneficiary of a social security scheme; * signed informed consent form Exclusion Criteria: * Patient group exclusion criteria: * no patient's relative for the control group; * known or suspective cognitive disorders prior to chemotherapy; * history of severe neurological or psychiatric disorders (e.g., severe depression); .previous chemotherapy; * previous brain radiotherapy; * ongoing treatments affecting cognition; * patient unable to read; * patient not speaking French; * person deprived of liberty by judicial or administrative decision; * person under forced psychiatric care; * person under legal protection measures; * person unable to express consent; .pregnant or breastfeeding woman. * Control group exclusion criteria: * known or suspected cognitive disorders; * history of severe neurological or psychiatric disorder (e.g., severe depression); .previous chemotherapy; * previous brain radiotherapy; * ongoing treatments affecting cognition; * person unable to read; * person not speaking French; * person deprived of liberty by judicial or administrative decision; * person under forced psychiatric care; * person under legal protection measures; * person unable to express consent; * pregnant or breastfeeding woman."
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07147621 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Myeloid Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07147621 currently recruiting?
Yes, NCT07147621 is actively recruiting participants. Contact the research team at AlSchmidt@chu-angers.fr for enrollment information.
Where is the NCT07147621 trial being conducted?
This trial is being conducted at Angers, France.
Who is sponsoring the NCT07147621 clinical trial?
NCT07147621 is sponsored by University Hospital, Angers. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.